Evaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults.
The hypothesis is that renal function will improve following tricuspid valve intervention. A reduction in renal biomarkers is also expected. Furthermore, based on previous assessments, it is anticipated that there will be an improvement in volume status (reduced edema), symptom burden, and physical capacity in patients. Additionally, the study will assess the impact of the intervention on functional parameters such as motor capacity, physical activity, performance of activities of daily living, and ultimately, participation and quality of life.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Severe symptomatic tricuspid valve insufficiency and referral for TriClip/TricValve screening
* Completed 18th year of life
* Ability to consent
* Able to walk short distances with aids
Exclusion Criteria:
* Dialysis-dependent/terminal kidney disease
* Inability to comply with study-associated assessments (e.g., existing dementia)
* Severe anemia (Hb \<7 g/dl)
* Tricuspid valve intervention with palliative intent and likely imminent death
* Lack of consent
Primary outcome measure(s)
Change in estimated glomerular filtration rate (eGFR) slope — Baseline, 6 months, 12 months, and 24 months Annual change in estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation based on serial serum creatinine measurements (ml/min/1.73m² per year)
Incidence of acute kidney injury (AKI) — Baseline, 6 months, 12 months, and 24 months Occurrence of acute kidney injury defined according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria based on changes in serum creatinine.
Physical activity assessed using the activPAL4 micro activity monitor — Baseline, 6 months, 12 months, and 24 months Physical activity measured over a 7-day monitoring period using the activPAL4 micro activity monitor (PAL Technologies, Glasgow, UK)
Change in functional exercise capacity assessed with the 6-minute walk test (6MWT) — Baseline, 6 months, 12 months, and 24 months Change in functional exercise capacity measured by the 6-minute walk test (6MWT)
Trial sites (1)
Facility
City
Region
Status
Robert Bosch Hospital
Stuttgart
Germany
Recruiting
More Robert Bosch Medical Center trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.